AstraZeneca PLC (AZN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
AstraZeneca PLC stock (AZN) is currently trading at $188.93. AstraZeneca PLC PE ratio is 29.25. AstraZeneca PLC PS ratio (Price-to-Sales) is 5.05. Analyst consensus price target for AZN is $193.43. WallStSmart rates AZN as Hold.
AstraZeneca PLC (AZN) stock price prediction for 2030: Base case $178.43. Bull case $223.04. Bear case $133.82. See full AZN 2030 price forecast and methodology on WallStSmart.
- AZN PE ratio analysis and historical PE chart
- AZN PS ratio (Price-to-Sales) history and trend
- AZN intrinsic value — DCF, Graham Number, EPV models
- AZN stock price prediction 2025 2026 2027 2028 2029 2030
- AZN fair value vs current price
- AZN insider transactions and insider buying
- Is AZN undervalued or overvalued?
- AstraZeneca PLC financial analysis — revenue, earnings, cash flow
- AZN Piotroski F-Score and Altman Z-Score
- AZN analyst price target and Smart Rating
AstraZeneca
📊 No data available
Try selecting a different time range
AZN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · AstraZeneca PLC (AZN)
AZN trades at a significant discount to its Graham intrinsic value of $306.07, offering a 33% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
AstraZeneca PLC (AZN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, operating margin. Concerns around price/book and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
AstraZeneca PLC (AZN) Key Strengths (6)
Mega-cap company, among the largest in the world
Earnings per share surging 53.90% year-over-year
Every $100 of equity generates $23 in profit
Strong operational efficiency: $22 kept per $100 revenue
Strong profitability: $17 kept per $100 revenue
56.56% held by institutions, strong professional interest
AstraZeneca PLC (AZN) Areas to Watch (4)
Very expensive at 6.1x book value
Revenue growing slowly at 4.10% annually
Premium valuation at 5.0x annual revenue
Growth is fairly priced, not cheap, not expensive
Supporting Valuation Data
AstraZeneca PLC (AZN) Detailed Analysis Report
Overall Assessment
This company scores 64/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 6 register as strengths (avg 8.8/10) while 4 fall into concern territory (avg 3.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with Return on Equity at 22.80%, Operating Margin at 21.60%, Profit Margin at 17.40%. Growth metrics are encouraging with EPS Growth at 53.90%.
The Bear Case
The primary concerns are Price/Book, Revenue Growth, Price/Sales. Some valuation metrics including PEG Ratio (1.56), Price/Sales (5.05), Price/Book (6.10) suggest expensive pricing. Growth concerns include Revenue Growth at 4.10%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 22.80% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 4.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Market Cap, EPS Growth) and negatives (Price/Book, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WallStSmart Analysis Synopsis
Data-driven financial summary for AstraZeneca PLC (AZN) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
AstraZeneca PLC is a strong growth company balancing expansion with improving profitability. Revenue reached 58.7B with 410% growth year-over-year. Profit margins of 17.4% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 410% YoY, reaching 58.7B. This pace significantly outperforms most DRUG MANUFACTURERS - GENERAL peers.
ROE of 2280.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can AstraZeneca PLC maintain 410%+ revenue growth, or will competition slow it down?
Debt management: total debt of 29.7B is significantly higher than cash (5.7B). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact AstraZeneca PLC.
Bottom Line
AstraZeneca PLC offers an attractive blend of growth (410% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 2:56:06 PM
About AstraZeneca PLC(AZN)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.